Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Laura Bender; Guillaume Meyer; Elisabeth Quoix; Bertrand Mennecier

doi:10.21037/atm.2019.01.24

Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Ann Transl Med. 2019 Mar;7(5):106. doi: 10.21037/atm.2019.01.24.

Authors

Laura Bender¹, Guillaume Meyer², Elisabeth Quoix³, Bertrand Mennecier³

Affiliations

¹ Department of Medical Oncology, University Hospital, Strasbourg, France.
² Department of Pharmacy, University Hospital, Strasbourg, France.
³ Department of Pneumology, University Hospital, Strasbourg, France.

Abstract

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.

Keywords: Anaplastic lymphoma kinase rearrangement (ALK rearrangement); ceritinib; diffuse interstitial pneumonitis; non-small cell lung cancer (NSCLC).

Publication types

Case Reports